KR20190050016A - Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient - Google Patents
Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient Download PDFInfo
- Publication number
- KR20190050016A KR20190050016A KR1020170145086A KR20170145086A KR20190050016A KR 20190050016 A KR20190050016 A KR 20190050016A KR 1020170145086 A KR1020170145086 A KR 1020170145086A KR 20170145086 A KR20170145086 A KR 20170145086A KR 20190050016 A KR20190050016 A KR 20190050016A
- Authority
- KR
- South Korea
- Prior art keywords
- food composition
- omega
- functional food
- health functional
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000036541 health Effects 0.000 title claims abstract description 36
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 23
- 206010013774 Dry eye Diseases 0.000 title claims abstract description 23
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 235000013376 functional food Nutrition 0.000 title claims description 30
- 230000002265 prevention Effects 0.000 title description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 23
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 12
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 12
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 12
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 6
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 6
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 6
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 6
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 210000001508 eye Anatomy 0.000 abstract description 8
- 235000013402 health food Nutrition 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 208000003464 asthenopia Diseases 0.000 abstract 1
- 230000009471 action Effects 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SLFHWLMXLIRLPS-DFWYDOINSA-N N[C@@H](CCC(N)=O)C(=O)O.[Na] Chemical compound N[C@@H](CCC(N)=O)C(=O)O.[Na] SLFHWLMXLIRLPS-DFWYDOINSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical class O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YIOCQGHBBNGBND-UHFFFAOYSA-N sodium;3-acetyl-6-methylpyran-3-ide-2,4-dione Chemical compound [Na+].CC(=O)[C-]1C(=O)C=C(C)OC1=O YIOCQGHBBNGBND-UHFFFAOYSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1874—Linolenic acid
Abstract
Description
본 발명은 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물에 관한 것이다.The present invention relates to a health functional food composition for preventing or improving ocular dryness including omega-3 as an active ingredient.
안구 건조증(dry eye syndrome)은 건성안증후군 또는 눈마름증후군으로 불리는 질환으로, 눈이 시리고 모래알이 들어간 듯한 이물감이 있으며, 눈이 쉽게 피로하여 잘 뜰 수가 없는 증상을 나타낸다. 발병기전은 아직 완전히 규명되지 않았으나, 염증 질환의 일종이라는 증거가 확보되고 있으며, 안구 건조증 환자의 눈물에는 정상인에 비해 IL-2, IL-4, IL-5, IL-6, IL-10, TNF-α 및 IL-1β 등의 염증 관련 사이토카인과 IL-8과 같은 염증 관련 케모카인이 과발현 됨이 보고되었다.Dry eye syndrome is a syndrome called dry eye syndrome or syndrome of the eye syndrome. It has a foreign body that is like eyeballs and sand, and shows symptoms that the eyes can not easily get tired due to easy fatigue. IL-4, IL-5, IL-6, IL-10, and TNF in the tears of patients with dry eye syndrome. -α and IL-1β, and inflammatory-related chemokines such as IL-8 have been reported to be overexpressed.
이러한 안구 건조증은 인공 눈물 안약이나 염증 치료 안약, 비타민 안약 등을 사용한 역물을 통해 치료할 수 있다. 안구건조증의 치료에 사용되는 약물의 예로서, 시클로스포린 A(Cyclosporin A), 플루오로메톨론(Fluorometholone) 등이 있다. 상기 시클로스포린 A는 면역 억제제로 널리 사용되는 약물이며, IL-2, IL-4, IL-12 등과 관련된 T 세포의 활성 및 생장을 저해하여 면역 시스템의 활성을 감소시켜 안구 표면의 염증을 감소시키는 효과를 나타낸다. 1,200 명을 대상으로 한 임상 시험에서는 15 % 정도의 사람들에게서 눈물 생산 증가 효과를 나타냈다. 그러나, 눈의 통증, 이물감, 가려움 등의 부작용을 발생시키며, 고용량으로 장기 사용할 경우에는 암의 발명 위험이 증가한다고 보고되었다. 또한, 플루오로메톨론은 코르티코스테로이드(Corticosteroid)로서, 레이저 기반의 굴정 수술 후에 가장 흔히 사용되는 약물이다. 플루오로메톨론-아세테이트 현탁액은 눈꺼풀 및 안구결막(bulbar conjunctive), 각막 및 안구의 앞쪽에 야기되는 스테로이드 반응성 염증 상태의 치료에 사용되고 있다.Such dry eye syndrome can be treated through artificial tear drops, anti inflammatory eye drops, vitamins eye drops, and the like. Examples of drugs used in the treatment of dry eye syndrome include Cyclosporin A, Fluorometholone, and the like. Cyclosporin A is widely used as an immunosuppressive agent and inhibits the activity and growth of T cells associated with IL-2, IL-4, and IL-12, thereby reducing the activity of the immune system, Effect. In a clinical trial of 1,200 people, tear production increased by about 15%. However, it causes side effects such as eye pain, foreign body sensation, and itching, and it has been reported that the long-term use at a high dose increases the risk of cancer. In addition, fluorometholone is a corticosteroid, the most commonly used drug after laser-based buccal surgery. Fluorometholone-acetate suspensions have been used to treat steroid-responsive inflammatory conditions caused by eyelids and bulbar conjunctivitis, corneas and anterior to the eye.
그러나, 안구 건조증은 우리나라 성인 20 % 내외로 발생하는 흔한 질병으로, 특히 세계적인 기후 변화, 특히 엘리뇨 현상으로 온도가 올라가고 있는 상황과 환경 오염으로 인해 안구 건조증 환자가 지속적으로 증가하고 있으나, 이를 예방 또는 개선하기 위한 특별한 건강 기능성 식품은 없는 상황이다.However, dry eye syndrome is a common disease that occurs in about 20% of adults in Korea. Especially, the global warming due to global climate change, especially El Niño phenomenon, and environmental pollution, There is no special health functional food for this.
한편, 오메가-3은 신경세포막과 망막에 분포하며, 세포막에서 전기적인 자극을 빠른 속도로 다음 세포에 전달하는 역할을 하는 것으로 알려져 있다. 또한 인체 안에서 세포를 보호하고, 세포의 구조를 유시시키며, 원활한 신진대사를 돕고, 혈액의 피막 형성을 억제하고, 뼈의 형성을 촉진시키는 효과가 있는 것으로 알려져 있다.On the other hand, omega-3 is distributed in the nerve cell membrane and the retina, and it is known that it plays a role of delivering electric stimulation to the next cell at a rapid rate in the cell membrane. It is also known that it has the effect of protecting the cells in the human body, stimulating the cell structure, assisting the smooth metabolism, inhibiting the formation of blood film, and promoting bone formation.
이에 본 발명가들은 본 발명의 오메가-3을 유효성분으로 포함하는 건강 기능성 식품조성물은 장기간 복용해도 부작용이 적으며, 독성이 거의 없고, 건조한 눈을 개선하여 눈 건강에 도움을 줄 수 있으며, 눈의 피로도 함께 예방 또는 개선할 수 있는 것은 발견하고 본 발명을 완성하였다.Accordingly, the inventors of the present invention found that the health functional food composition containing the omega-3 as an active ingredient of the present invention has little side effects even when taken for a long period of time, has little toxicity, can improve dry eyes, Fatigue can be prevented or improved together, and the present invention has been completed.
본 발명의 목적은 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물을 제공하는 것이다.It is an object of the present invention to provide a health functional food composition for preventing or ameliorating dry eye syndrome containing omega-3 as an active ingredient.
또한, 본 발명의 목적은 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물을 제조하는 방법을 제공하는 것이다.It is also an object of the present invention to provide a method for preparing a health functional food composition for preventing or ameliorating dry eye syndrome containing omega-3 as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for preventing or ameliorating dry eye syndrome comprising omega-3 as an active ingredient.
본 발명에 있어서, 상기 오메가-3은 에이코사펜타엔산(EPA), 도코사헥사엔산(DHA), 알파-리놀렌산(ALA), 스테아리돈산(SA) 또는 이들의 조합으로 구성되는 군으로부터 선택될 수 있으며, 바람직하게는 에이코사펜타엔산(EPA) 및 도코사헥사엔산(DHA)일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the omega-3 is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearidonic acid (SA) , Preferably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), but is not limited thereto.
본 발명의 건강 기능성 식품조성물은 총 조성물의 중량 대비 오메가-3을 0.001 내지 90 중량%로 포함할 수 있으며, 구체적으로 0.1 내지 70 중량%로 포함할 수 있으나, 이에 제한되는 것은 아니다. The health functional food composition of the present invention may contain 0.001 to 90% by weight, specifically 0.1 to 70% by weight, of omega-3 relative to the weight of the total composition, but is not limited thereto.
본 발명의 건강 기능성 식품조성물의 일 예로, 캡슐제로 사용될 수 있으며, 이 경우 통상의 캡슐제와 같이 여러 가지 추가 성분을 함유할 수 있다.As an example of the health functional food composition of the present invention, it can be used as a capsule, and in this case, it may contain various additional components such as a conventional capsule.
본 발명에 따른 오메가-3을 유효성분으로 포함하는 건강 기능성 식품조성물은 장기간 복용해도 부작용이 적으며, 독성이 거의 없고, 건조한 눈을 개선하여 눈 건강에 도움을 줄 수 있으며, 눈의 피로도 함께 예방 또는 개선할 수 있는, 우수한 안구 건조증의 예방 또는 개선 효과가 있다.The health functional food composition containing omega-3 as an active ingredient according to the present invention has little side effects even when taken for a long period of time, has little toxicity, can improve dry eyes and can help the eye health, Or improvement of dry eye syndrome.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해 질 것이다. 그러나, 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있으며, 단지 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하세 알려 주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Brief Description of the Drawings The advantages and features of the present invention and how to accomplish them will become apparent with reference to the embodiments described in detail below. However, it is to be understood that the present invention is not limited to the embodiments disclosed herein but may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. To fully disclose the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
본 발명은 오메가-3을 유효성분으로 포함하는 안구 건조증의 예방 또는 개선용 건강 기능성 식품조성물을 제공한다.The present invention provides a health functional food composition for preventing or ameliorating dry eye syndrome comprising omega-3 as an active ingredient.
이하, 본 명세서에 대하여 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 있어서, 상기 오메가-3(omega-3)은 일반적으로 오메가-3 지방산으로, 탄소 사슬의 끝에서 세 번째 탄소에서부터 이중 결합(C=C)이 시작되는 필수 불포화 지방산으로, 탄소 사슬 양 끝은 카르복시기(COOH)와 메틸(CH3)기인 구조인 것을 의미한다.In the present invention, the omega-3 is an omega-3 fatty acid, an essential unsaturated fatty acid in which a double bond (C = C) starts from the third carbon at the end of the carbon chain, (COOH) and a methyl (CH 3 ) group.
본 발명에 있어서, 상기 오메가-3은 에이코사펜타엔산(EPA), 도코사헥사엔산(DHA), 알파-리놀렌산(ALA), 스테아리돈산(SA) 또는 이들의 조합으로 구성되는 군으로부터 선택될 수 있으며, 바람직하게는 에이코사펜타엔산(EPA) 및 도코사헥사엔산(DHA)일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the omega-3 is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearidonic acid (SA) , Preferably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), but is not limited thereto.
본 발명에 있어서, 상기 “안구 건조증(dry eye syndrome)”이란 안구 표면이 손상되어 자극감, 이물감 또는 건조감과 같은 자극 증상을 느끼게 되는 눈의 질환을 의미한다.In the present invention, the term " dry eye syndrome " refers to a disease of the eye that is irritated by irritation, foreign body sensation, or dry feeling due to damage to the surface of the eye.
본 발명에 있어서, 상기 “예방”이란 상기 오메가-3을 유효성분으로 포함하는 건강 기능성 식품조성물의 섭취로 인해 안구 건조증을 억제 또는 지연시키는 모든 행위는 의미한다. In the present invention, the term " prevention " means any action that inhibits or delays dryness of the eye due to ingestion of the health functional food composition containing the omega-3 as an active ingredient.
본 발명에 있어서, 상기 “개선”이란 상기 오메가-3을 유효성분으로 포함하는 건강 기능성 식품조성물의 섭취로 인해 안구 건조증의 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.In the present invention, the term " improvement " means any action that improves or alleviates the symptoms of dry eye syndrome due to ingestion of the health functional food composition containing the omega-3 as an active ingredient.
본 발명의 구체적인 일 실시예에 있어서, 안구건조증이 유도된 인간 각막 상피세포에 본 발명의 건강 기능 식품조성물을 처리한 결과, 각막 상피세포의 사멸 및 형태 변경이 억제되고, 세포사멸 단백질이 억제되며, 염증 유발 사이토카인 TNF-α, IL-β 또는 IL-6의 단백질 등의 발현량이 현저하게 감소되는 것을 확인하였다. 이는 본 발명의 오메가-3를 유효성분으로 포함하는 본 발명의 건강 기능성 식품조성물이 안구 건조증에 유효성분으로 사용될 수 있음을 시사하는 것이다.In one specific embodiment of the present invention, treating the health functional food composition of the present invention with human corneal epithelial cells in which dry eye syndrome is induced results in inhibition of apoptosis and morphological changes of corneal epithelial cells, inhibition of apoptotic proteins , The expression level of inflammatory cytokines such as TNF-α, IL-β or IL-6 protein was markedly decreased. This suggests that the health functional food composition of the present invention containing omega-3 as an active ingredient of the present invention can be used as an effective ingredient in dry eye syndrome.
본 발명의 건강 기능성 식품조성물은 총 조성물의 중량 대비 오메가-3을 0.001 내지 90 중량%로 포함할 수 있으며, 구체적으로 0.1 내지 70 중량%로 포함할 수 있으나, 이에 제한되는 것은 아니다. The health functional food composition of the present invention may contain 0.001 to 90% by weight, specifically 0.1 to 70% by weight, of omega-3 relative to the weight of the total composition, but is not limited thereto.
본 발명의 건강 기능성 식품조성물은 일상적으로 섭취하는 것이 가능하기 때문에 안구 건조증의 개선 효과를 기대할 수 있으므로, 건강 증진 목적으로 매우 유용하게 사용될 수 있다.Since the health functional food composition of the present invention can be ingested routinely, it can be expected to improve the dry eye syndrome and thus can be very useful for health promotion purposes.
본 발명에 있어서, 상기 “기능성 식물(functional food)”이란 특정 보건용 식품(food for special health use, FoSHU)과 동일한 용어로, 영양 공급 외에도 생체 조절 기능이 효율적으로 나타나도록 가공된 의학, 의료 효과가 높은 식품을 의미한다. 여기서 “기능성”이란 인체의 구조 및 기능에 대하여 영양소를 조정하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것은 의미한다.In the present invention, the term " functional food " refers to a food for special health use (FoSHU) Means high food. Here, "functional" means that the structure and function of the human body are adjusted to the nutrients or obtained a beneficial effect for health use such as physiological action.
본 발명에 있어서, 상기 “건강 식품(health food)”이란 일반 식품에 비해 적극적인 건강 유지나 증진 효과를 가지는 식품을 의미하고, “건강 보조 식품(health supplement food)”이란 건강 보조 목적의 식품을 의미한다. 경우에 따라, 건강 기능 식품, 건강 식품 또는 건강 보조 식품의 용어 호용된다.In the present invention, the above-mentioned " health food " means a food having an active health promotion or promotion effect as compared with a general food, and " health supplement food " . In some cases, the term health food, health food or health supplement is used.
본 발명의 식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다.The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art.
구체적으로, 상기 건강 기능성 식품조성물은 음료, 차류, 향신료, 껌 또는 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화 또는 현탁액 등으로 제조한 식품으로, 바람직하게는 캡슐화로 제조할 수 있으나, 이에 제한되는 것은 아니다. Specifically, the health functional food composition may be added to food materials such as beverage, tea, spice, gum or confection, or may be prepared by encapsulation, preferably by encapsulation, powder, or suspension. But is not limited to.
상기와 같이 제조된 본 발명의 건강 기능성 식품조성물을 섭취할 경우 건강상 특정한 효과를 가져 오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장이 복용 시 발생할 수 있는 부작용이 없는 장점이 있다.When the health functional food composition of the present invention prepared as described above is ingested, it means that it brings about a health-specific effect. However, unlike general medicines, it has a merit that a food is used as a raw material and there is no side effect have.
상기 건강 기능성 식품조성물은 생리학적으로 허용 가능하는 담체를 추가로 포함할 수 있으나, 담체의 종류는 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용될 수 있다.The health functional food composition may further include a physiologically acceptable carrier, but the carrier is not particularly limited and any carrier conventionally used in the art can be used.
또한, 상기 건강 기능성 식품조성물에 통상 사용되어 냄새, 맛 또는 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예를 들어, 비타민 A, C, D, E B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate) 또는 판토텐산(panthotenic aicd) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 또는 크륨(Cr) 등의 미네랄; 및 라이신, 트립토판, 시스테인 또는 발린 등의 아미노산을 포함할 수 있다.In addition, it may contain additional components that are commonly used in the health functional food composition and can improve the odor, taste or visual appearance. For example, vitamins A, C, D, E B1, B2, B6, B12, niacin, biotin, folate or panthotenic acid. Minerals such as Zn, Fe, Ca, Cr, Mg, Mn, Cu, or Cr; And amino acids such as lysine, tryptophan, cysteine or valine.
또한, 상기 건강 기능성 식품조성물은 방부제(소르빈산 칼륨, 벤조산 나트륨, 살리실산 또는 데히드로초산 나트륨 등), 살균제(표백분, 고도 표백분 또는 차아염소산 나트륨 등), 산화방지제(부틱히드록시아니졸(BHA) 또는 부틸히드록시톨루엔(BHT) 등), 착색제(타르 색소 등), 박색제(아질산 나트륨 또는 아초산 나트륨 등), 표백제(아황산 나트륨 등), 조미료(글루타민 나트륨 등), 감미료(둘신, 사이클레메이트, 사카린 또는 나트륨 등), 향료(바닐린 또는 락톤류 등), 팽창제(명반 또는 D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 검품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.In addition, the health functional food composition may contain at least one selected from the group consisting of preservatives (potassium sorbate, sodium benzoate, salicylic acid or dehydroacetic acid sodium), disinfectants (such as bleaching powder, highly bleached white or sodium hypochlorite), antioxidants (bactic hydroxyanisole (Sodium hypophosphite, etc.), seasoning (sodium glutamine, etc.), sweeteners (hypochlorite, cyclamate, etc.), coloring agents (tar pigments, etc.), coloring agents (sodium nitrite or sodium nitrate, (Such as alginic acid or sodium salt), perfume (such as vanillin or lactones), a swelling agent (such as alum or potassium hydrogen D-tartrate), an emulsifier, a thickening agent, a coating agent, a gum base agent, Of food additives. The additives may be selected and used in appropriate amounts depending on the type of food.
본 발명의 건강 기능성 식품조성물의 일 예로, 캡슐제로 사용될 수 있으며, 이 경우 통상의 캡슐제와 같이 여러 가지 추가 성분을 함유할 수 있다.As an example of the health functional food composition of the present invention, it can be used as a capsule, and in this case, it may contain various additional components such as a conventional capsule.
본 발명의 건강 기능성 식품조성물은 상기 외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다.The health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, Preservatives, glycerin, alcohols or carbonating agents, and the like.
이상 설명으로부터, 본 발명에 속하는 기술 분야의 당업자는 본 발명의 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며, 한정적인 것이 아닌 것으로서 이해해야만 한다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. In this regard, it should be understood that the above-described embodiments are illustrative in all aspects and not restrictive.
Claims (6)
The health functional food composition of claim 1, wherein the food composition is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170145086A KR20190050016A (en) | 2017-11-02 | 2017-11-02 | Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170145086A KR20190050016A (en) | 2017-11-02 | 2017-11-02 | Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190050016A true KR20190050016A (en) | 2019-05-10 |
Family
ID=66580618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170145086A KR20190050016A (en) | 2017-11-02 | 2017-11-02 | Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20190050016A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220002796A (en) * | 2020-06-30 | 2022-01-07 | (주)에이앤바이오 | Composition for improving dry eyes and preventing tear pigmentation for pets |
-
2017
- 2017-11-02 KR KR1020170145086A patent/KR20190050016A/en unknown
Non-Patent Citations (3)
| Title |
|---|
| Dantal J., 1998, The Lancet 351(9103): 623-628. |
| Massingale ML., 2009, Coenea, 28(9): 1023-1027. |
| Michelle Meadows, 2005, FDA Consumer Magazine. |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220002796A (en) * | 2020-06-30 | 2022-01-07 | (주)에이앤바이오 | Composition for improving dry eyes and preventing tear pigmentation for pets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5574561B2 (en) | Total enteral nutrition composition | |
| TWI487520B (en) | Anti-fatigue agents and oral compositions with andrographolide as active ingredients | |
| KR102566670B1 (en) | skin pigmentation inhibitor | |
| WO2009002146A1 (en) | Supporting activities of daily living | |
| US8703789B2 (en) | Compositions incorporating sesamin-class compounds and vitamin B1 class compounds | |
| JP5604673B2 (en) | Composition for recovery or prevention of fatigue of central nervous system | |
| KR102418096B1 (en) | Composition for maintaining effect of filler | |
| WO2014069660A1 (en) | Blood flow promoting agent | |
| JP6775419B2 (en) | Composition for prevention or improvement of peripheral neuropathy | |
| EP3461479B1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
| JP4812968B2 (en) | Composition for improving attention deficit / hyperactivity disorder | |
| KR20190050016A (en) | Health Functional Food Composition for the Prevention or Alleviation of Dry Eye Syndrome Comprising the Omega-3 as an Active Ingredient | |
| CN107788526A (en) | A kind of nutriment for protecting Bones and joints | |
| EP3290041B1 (en) | Oral care composition | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| JP2005213185A (en) | Energy-supplementary and anti-fatigue food and beverage | |
| KR102141623B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of cinnamon | |
| EP3024450B1 (en) | Compositions and methods using tiglic aldehyde | |
| JP7057150B2 (en) | Oral liquid | |
| KR20100008400A (en) | The composition for the atopic dermatitis improving with vinegar | |
| WO2005082371A2 (en) | Oral dieting composition comprising conjugated linoleic acid and caffeine | |
| KR20190050006A (en) | Health Functional Food Composition for the Prevention or Alleviation of Age-related Macular Degeneration Comprising the Extracts of Marigold | |
| WO2016174861A1 (en) | Oral care composition | |
| BE1026122A1 (en) | Composition for preventing or reducing the effects of alcohol poisoning | |
| JP2018058828A (en) | Leucine derivatives, compositions comprising the same, and applications thereof |